1. Home
  2. BMBL vs PEPG Comparison

BMBL vs PEPG Comparison

Compare BMBL & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

HOLD

Current Price

$4.09

Market Cap

425.0M

Sector

Technology

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$1.72

Market Cap

113.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMBL
PEPG
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.0M
113.3M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
BMBL
PEPG
Price
$4.09
$1.72
Analyst Decision
Hold
Strong Buy
Analyst Count
14
6
Target Price
$4.42
$11.17
AVG Volume (30 Days)
3.4M
2.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.61
EPS
N/A
N/A
Revenue
$965,658,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.61
$1.01
52 Week High
$8.63
$7.80

Technical Indicators

Market Signals
Indicator
BMBL
PEPG
Relative Strength Index (RSI) 69.82 21.57
Support Level $3.21 $1.17
Resistance Level $4.31 $5.46
Average True Range (ATR) 0.19 0.28
MACD 0.05 -0.06
Stochastic Oscillator 96.37 10.00

Price Performance

Historical Comparison
BMBL
PEPG

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: